Table 1 Characteristics of the study population
Total (n = 108) | Antagonist protocol (n = 54) | PPOS protocol (n = 54) | p-value | |
|---|---|---|---|---|
Age (years) (mean ± SD) | 30.3 ± 4.3 | 30.8 ± 4.6 | 29.7 ± 4.0 | 0.191 |
BMI (kg/m2)(mean ± SD) | 22.2 ± 4.1 | 21.9 ± 2.6 | 22.6 ± 5.1 | 0.351 |
Smoking (%(n)) | 31.5% (34/108) | 33% | 29% | 0.682 |
Positive gravidity (%(n)) | 20.5% (22/108) | 22% | 19% | 0.422 |
Positive parity (%(n)) | 6.5% (7/108) | 6% | 7% | 0.702 |
Prior ovarian surgery (%(n)) | 27.8% (30/108) | 31% | 24% | 0.392 |
Prior surgery for endometrioma (%(n)) | 21.5% (23/107) | 26% | 17% | 0.222 |
Prior surgery for endometriosis (%(n)) | 20.8% (22/106) | 17% | 25% | 0.342 |
AMH (ng/ml) (mean ± SD) | 2.1 ± 1,9 | 2.1 ± 2.4 | 2 ± 1.3 | 0.821 |
AFC (n) (mean ± SD) | 11.3 ± 6,8 | 11.1 ± 7.4 | 11.5 ± 6.2 | 0.751 |
Endometrioma during the FP (%(n)) | 34.3% (36/105) | 31% | 38% | 0.452 |
DE (%(n)) | 92.1% (93/101) | 92% | 92% | 0.932 |
DE with digestive involvement (%(n)) | 42.7% (41/96) | 35% | 49% | 0.162 |
Adenomyosis (%(n)) | 25.5% (25/98) | 25% | 27% | 0.822 |
Oral progestin treatment before FP(%(n)) | 82.2% (88/107) | 76% | 89% | 0.082 |